Tirzepatide
Neutral technical record and index of the peer-reviewed literature referencing Tirzepatide. For research use only — no human or veterinary use, benefit, or dosing information is provided.
Identity
| PubChem CID | 166567236 |
|---|---|
| CAS number | 2023788-19-2 |
| Molecular formula | C225H348N48O68 |
| Molecular weight | 4813 g/mol |
| InChIKey | BTSOGEDATSQOAF-MCNPHUAVSA-N |
What it is
Tirzepatide is a synthetic peptide that acts as a dual receptor agonist. It belongs to the class of incretin-based agonists, targeting the GIP and GLP-1 receptors. It is supplied as lyophilized material for research use only.
Mechanism (technical)
Tirzepatide has been studied for its dual agonist action on GIP and GLP-1 receptors, pathways associated with glucose regulation and energy balance. This mechanism has been investigated in phase 3 metabolic trials. Endpoints have characterized body weight, glycemic parameters, and kidney measures.
Peer-reviewed literature
4 studies indexed · 4 human. Listed neutrally; outcome studies are indexed, not endorsed.
- Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5)Aronne LJ, et al. · 2025 · N Engl J Med · RCT · human
- Tirzepatide for Weight Reduction in Chinese Adults With Obesity (SURMOUNT-CN)Zhao L, et al. · 2024 · JAMA · RCT · human
- Tirzepatide vs insulin glargine on kidney outcomes in T2D (SURPASS-4 post-hoc)Heerspink HJL, et al. · 2022 · Lancet Diabetes Endocrinol · RCT · human
- Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)Jastreboff AM, et al. · 2022 · N Engl J Med · RCT · human
For research use only. Not for human or veterinary use. Not a drug, food, cosmetic, or dietary supplement. Sold to qualified researchers for laboratory research purposes only.